Insights

Low interest rates are a big issue for anyone relying on income from bank deposits. But be wary of investments marketed as being 'like' term deposits - they can come with far more risk.

We take a look at managed portfolios and if COVID-19 has changed their asset weightings.

As a tough period ahead weighs on the share price of the Big Four banks, and Directors’ participation in capital raisings continue, Alex Gluyas runs through another fortnight dominated by insider buying.

Since late February we've seen intense volatility on the Aussie sharemarket. This has driven a massive uptick in the number of people trying to make a quick buck on shares. But not many have succeeded.

Join Nathan, Evan, and Tom as they dicuss COVID-19s effect on disappearing dividends.

With online retail sales surging, Alex Gluyas looks at how COVID-19 restrictions and changing consumption habits has led to a boom in the major buy now pay later platforms.

Alan Kohler speaks with the CEO of InvestSMART Group, Ron Hodge, about how the company plans to replace revenue it will lose from the incoming removal of grandfathered trailing commissions, its mantra of capping fees and the surge in subscriptions for Intelligent Investor and Eureka Report.

April saw all four InvestSMART Diversified Capped Fee portfolios outperform peers and Evan Lucas highlights, the key to good long-term returns comes from developing positive investment habits rather than timing the market.

Steve Sammartino explores how Amazon is investing in a COVID-safe supply chain, and the concept of exo-labour, where work is undertaken remotely through augmentation tools and how this will contribute to the post-COVID-19 recovery.

For many Australians, especially retirees, dividends are a source of reliable and tax-friendly income. But with a number of companies abandoning dividend payments, the hunt is on for alternate sources of cash.

Part Two questions the strength of Australian banks during the COVID-19 crisis.

In line with the last two months of insider transactions, Alex Gluyas looks at another three weeks dominating by Directors topping up their stake and a few huge sells that have made headlines.

Robert Gottliebsen delves into the differing economic forecasts presented by the trading banks and the Reserve Bank and the impact each perspective might have on house prices and share values.

We look at whether banks are still a safe investment and how COVID-19 has impacted their bottom lines.

Our CEO Ron Hodge recently shared how he is investing during a crisis. Today, our Chairman, Paul Clitheroe gives us his go-to strategy during these times.

After releasing promising results from a small trial on COVID-19 patients with ARDS last Friday, Alex Gluyas looks into how Mesoblast’s upcoming clinical trial results and potential FDA approval could impact its valuation.